Abstract
The time course and duration of action of drugs used in cancer chemotherapy are greatly influenced by the molecular and biochemical properties of enzymes associated with their metabolism. Variation in the response of individual patients to cancer chemotherapeutic agents is in large measure due to genetic and environmental factors that impinge on specific enzymes belonging to the two major classes of drug metabolizing enzymes. Current knowledge of the molecular biology and biochemistry of phase I drug metabolizing enzymes (cytochrome P450, flavin-containing and xanthine oxidases, NADPH quinone reductase, and aldehyde and dihydropyridine dehydrogenases), and phase II enzymes (glucuronosyl-, sulfo-, N-acetyl-, and glutathione transferases, and hydrolases) is reviewed briefly. Advances in understanding genetic and environmental factors that influence activities of phase I and phase II pathways of drug metabolism are discussed in the first sections of this review followed by a consideration of the influence of drug metabolism on the actions of agents currently used in the treatment of cancer. Emphasis is given to drugs that have recently been introduced into the armamentarium of cancer chemotherapy including inhibitors of chromatin function, target-based inhibitors of signal transduction and cyclin-dependent kinases, and angiogenesis inhibitors acting on metalloproteinases, epithelial cell growth, angiogenesis stimulation, and endothelial-specific integrins.
Keywords: Cancer Drug Design, cancer chemotherapy, NADPH quinone reductase, chromatin function, angiogenesis stimulation, antineoplastic, cynomolgus monkeys, Genetic Polymorphism, nutritional impairment, Cytochrome P450, fish malodor syndrome, Xanthine oxidase, Eniluracil, blood-brain barrier, Crigler-Najjar syndrome, DNA-binding drugs, BLM-hydrolase, Exatecan mesylate, Etoposide and teniposide, Matrix Metalloproteinases
Current Cancer Drug Targets
Title: Challenges of Cancer Drug Design A Drug Metabolism Perspective
Volume: 1 Issue: 1
Author(s): R. I. Sanchez, S. Mesia-Vela and F. C. Kauffman
Affiliation:
Keywords: Cancer Drug Design, cancer chemotherapy, NADPH quinone reductase, chromatin function, angiogenesis stimulation, antineoplastic, cynomolgus monkeys, Genetic Polymorphism, nutritional impairment, Cytochrome P450, fish malodor syndrome, Xanthine oxidase, Eniluracil, blood-brain barrier, Crigler-Najjar syndrome, DNA-binding drugs, BLM-hydrolase, Exatecan mesylate, Etoposide and teniposide, Matrix Metalloproteinases
Abstract: The time course and duration of action of drugs used in cancer chemotherapy are greatly influenced by the molecular and biochemical properties of enzymes associated with their metabolism. Variation in the response of individual patients to cancer chemotherapeutic agents is in large measure due to genetic and environmental factors that impinge on specific enzymes belonging to the two major classes of drug metabolizing enzymes. Current knowledge of the molecular biology and biochemistry of phase I drug metabolizing enzymes (cytochrome P450, flavin-containing and xanthine oxidases, NADPH quinone reductase, and aldehyde and dihydropyridine dehydrogenases), and phase II enzymes (glucuronosyl-, sulfo-, N-acetyl-, and glutathione transferases, and hydrolases) is reviewed briefly. Advances in understanding genetic and environmental factors that influence activities of phase I and phase II pathways of drug metabolism are discussed in the first sections of this review followed by a consideration of the influence of drug metabolism on the actions of agents currently used in the treatment of cancer. Emphasis is given to drugs that have recently been introduced into the armamentarium of cancer chemotherapy including inhibitors of chromatin function, target-based inhibitors of signal transduction and cyclin-dependent kinases, and angiogenesis inhibitors acting on metalloproteinases, epithelial cell growth, angiogenesis stimulation, and endothelial-specific integrins.
Export Options
About this article
Cite this article as:
Sanchez I. R., Mesia-Vela S. and Kauffman C. F., Challenges of Cancer Drug Design A Drug Metabolism Perspective, Current Cancer Drug Targets 2001; 1 (1) . https://dx.doi.org/10.2174/1568009013334296
DOI https://dx.doi.org/10.2174/1568009013334296 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Functional and Structural Benefits Induced by Omega-3 Polyunsaturated Fatty Acids During Aging
Current Neuropharmacology In Vitro - In Vivo Correlation of Gene Expression Alterations Induced by Liver Carcinogens
Current Medicinal Chemistry Photodynamic Inactivation of Bacteria
Current Bioactive Compounds Drug Evolution Concept in Drug Design: 2. Chimera Method
Medicinal Chemistry Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Autologous Adipose-Derived Regenerative Cells for Therapeutic Angiogenesis
Current Pharmaceutical Design Protease Analysis by Zymography: A Review on Techniques and Patents
Recent Patents on Biotechnology Author Index To Volume 3
Current Topics in Medicinal Chemistry Effect of Short-term Quercetin, Caloric Restriction and Combined Treatment on Age-related Oxidative Stress Markers in the Rat Cerebral Cortex
CNS & Neurological Disorders - Drug Targets Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology Role of Chromatography for Monitoring of Breast Cancer Biomarkers
Recent Patents on Biomarkers Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis
Current HIV Research H+-myo-Inositol Transporter SLC2A13 as a Potential Marker for Cancer Stem Cells in an Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals
Current Topics in Medicinal Chemistry Carrier Mediated Systemic Delivery of Protein and Peptide Therapeutics
Current Pharmaceutical Design Triple Negative Breast Cancer: A Tale of Two Decades
Anti-Cancer Agents in Medicinal Chemistry Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Development of Colon Specific Microspheres of Flurbiprofen for Inflammatory Bowel Disease
Current Drug Delivery